2. Use of Antibacterials in Poultry and it’s Limitations Dr. Prakash Nadoor

USE OF ANTIBACTERIALS IN POULTRY AND IT’S LIMITATIONSPÉÆÃ½ GvÁàzÀ£ÉAiÀÄ°è ¸ÀÆPÁëöätÄ ¤gÉÆÃzsÀPÀUÀ¼À ¸ÀzÀã¼ÀPÉ ºÁUÀÄ

CzÀgÀ Ew-«ÄwUÀ¼ÀÄ

¥ÀæPÁ±ï £ÀqÀÆgï JA.«.J¹ì., ¦.ºÉZï.r ¥ÁæzsÁå¥ÀPÀgÀÄ ªÀÄvÀÄÛ ªÀÄÄRå¸ÀÛgÀÄ ¥À±ÀÄ ªÉÊzÀåQÃAiÀÄ OµÀzsÀ ±Á¸ÀÛç ªÀÄvÀÄÛ «µÀ

±Á¸ÀÛç «¨sÁUÀPÉ«JJ¥sóïJ¸ïAiÀÄÄ, ¥À±ÀÄ ªÉÊzÀåQÃAiÀÄ

ªÀÄºÁ«zÁå®AiÀÄ ²ªÀªÉÆUÀÎ [email protected]

PÉÆÃ½ GvÁàzÀ£É: 2020 (FAO)

¨ÉÃrPÉAiÀÄ ªÀÄÄAzÀÄªÀjPÉUÀ¼ÀÄ

¨sÁgÀvÀ

ªÀµÀð: 1993

ªÀÄÄAzÀÄªÀjPÉAiÀÄ

ªÀµÀð: 2020

C©üªÀÈü¢ÝAiÀÄ zÀgÀ %

[Growth rate] ªÀµÀð: 1993 -

2020

PÉÆÃ½ ªÀiÁA¸À [«ÄÃ°AiÀÄ£ï l£ï]

0.25 1.23 6.47

ªÉÆmÉÖ [©°AiÀÄ£ï] 9.30 79.10 8.48

eÁ£ÀÄªÁgÀÄ[JªÉÄä,zÀ£À] ªÀiÁA¸À [«ÄÃ°AiÀÄ£ï l£ï]

0.49 1.45 4.41

19902015PARAMETER YAER 1990 YEAR 2015

Broiler parents housed (cr) 0.7 3.5Broilers/month (crore) 5 25

Broiler feed price (Rs/kg) 20 30Chicken per head (kg) 0.4 2.5

Broiler price/kg live (Rs) 25 65Broiler integration 0% 60%

Broiler FCR 2.2 1.65Days to slaughter (2 kg) 48 38

Multi-age group farms 90% 10%Chicken processing 1% 7%

Antibiotics issue Nil 50%

¸ÀÆPÁëöätÄ

¤gÉÆÃzsÀPÀUÀ¼ÀÄ

E®è 50%

®¨sÀå«gÀÄªÀ ¸ÀÆPÁëöätÄ ¤gÉÆÃzsÀPÀUÀ¼ÀÄ

– ¸À¯Áá£ÁªÉÄÊqïì– £ÉÊmÉÆæ¥ÀÇgÁeÉÆ£ïì

*– ¥É¤ì°£ïì– ¸ÉÃ¥sÁ¯ÉÆÃ¸ÉÆàÃj£ïì – mÉmÁæ¸ÉÊQèÃ£ïì– CªÉÄÊì£ÉÆÃUÉèöÊPÉÆ

Ã¸ÉÊqïì– PÉÆèÃgÁA¦üí¤PÁ¯ï*– ªÀiÁåPÉÆæÃ°qïì – ¥ÉÇèÃgÉÆªÀÄÄn°Ã£ïì – DAiÀiÁ£ÉÆÃ¥sÉÇ¸ïð – ¥sÉÇèÃgÉÆÃQé£Á¯ÉÆ£ï

ì s– ¸ÉÖçÖ¥sÉÇÖÃUÁæ÷å«Ä

£ïì– E¤ßvÀgÉ

¤ªÀÄä DAiÉÄÌ ºÉÃVgÀ¨ÉÃPÀÄ

?

fÃªÁtÄ ¤gÉÆÃzsÀPÀUÀ¼À OµÀzsÀ

¸ÀÆa§gÀºÀzÀ ¤AiÀÄªÀÄUÀ¼ÀÄ FARM to PLATE CONCEPT

vÁvÁÌ°PÀªÁV PÁ¬Ä¯É ¥ÀvÉÛ ºÀZÀÄÑªÀÅzÀÄ ªÀÄvÀÄÛ OµÀzsÀ ¸ÀÆa§gÀºÀ (?)

fÃªÁtÄ ¤gÉÆÃzsÀPÀUÀ¼À ¸ÀÆPÀë÷ävÉAiÀÄ ¥ÀjÃPÉë (?)

¨ÉÃPÁVgÀÄªÀ OµÀ¢ü ¸ÀÆwæPÀgÀtzÀ ®¨sÀåvÉ (?)

¸ÀtÚ ªÀÄvÀÄÛ M¥ÉÇàwÛ£À PÉÆÃ½ ¸ÁPÁtÂPÉzÁgÀgÀ°è OµÀzsÉÆÃ¥ÀZÀgÀzÀ §UÉÎ EgÀÄªÀ vÁAwæPÀ w¼ÀÄªÀ½PÉ/CjªÀÅ.(?)

ªÀåªÀjPÀªÁV OµÀ¢üAiÀÄÄ ¥ÀæAiÉÆÃd¤ÃAiÀÄªÉÃ (?)

¥ÀæZÀ°vÀ ¸ÀªÀÄ¸ÉåUÀ¼ÀÄ

• CAn§AiÉÆÃnPï gÉ¹¸ÀÖ£Àì (Antibiotic resistance)

• CAn§AiÉÆÃnPï ±ÉÃµÁA±À (Antibiotic residue)

• ªÀiÁgÀÄPÀmÉÖ – CqÀØ¥ÀjuÁªÀÄ (Impact on

Trade)

• ¸ÁªÀðd¤PÀ DgÉÆÃUÀå (Impact on public health)

PK-PD integration of enrofloxacin (per os) based on observed or hypothetical MIC values

Parameter Observed MIC(μg.ml-1)

Hypothetical MIC (μg.ml-1)

Ratio (Mean +SE)

Inference

CMax./ MIC E. coli (0119) : 0.125 - 8.40 + 0.34 Satisfactory S. typhimurium: 0.125 -

- 0.01 104.50 + 4.95 Good

- 0.10 10.52 + 0.42 Satisfactory - 0.25 4.20 + 0.17 Not effective - 0.50 2.10 + 0.08 Not effective

Breakpoint > 8.0AUC(0-24h)/ MIC

E. coli (0119) : 0.125 - 30.48 +4.98 Moderate

S. typhimurium:0.125 -- 0.01 381.0 + 62.2 Good - 0.10 38.10 + 6.22 Moderate - 0.25 15.24 + 2.49 Not effective - 0.50 7.62 + 1.24 Not effective

Breakpoint > 100

(Prakash et. al., 2016, KVAFSU project)

CAn§AiÉÆÃnPï gÉ¹¸ÀÖ£Àì (Antibiotic

resistance)

Tissue levels (ppb) of enrofloxacin and ciprofloxacin after the withdrawal of enrofloxacin administration (10mg.kg-1 x 5days; per os) in broiler chickens

Time (hr.)

Breast muscle Liver

Kidney

ENRO CIPRO ENRO CIPRO ENRO CIPRO 24 126+ 8.48a 73.0+ 7.07a 445 + 21.2a 515+ 8.48a 316.5+ 9.19a 414.0+ 22.62a

48 30.5+ 2.12b 29.0+ 4.24b 82.0+ 5.65b 161.5+ 4.95b 165.5+ 6.36b 181.5+ 4.94b

72 1.60+ 0.84c 0.71+ 0.01c 10.0+ 2.82c 19.0+ 4.24c 10.75+ 3.89c 4.05+ 0.21c

96 N.D N.D N.D 0.36+ 0.08d N.D 0.22+ 0.02d

Note: a. ENRO=Enrofloxacin; CIPRO= Ciprofloxacin; b. LOD: 0.01ug.ml-1 ; LOQ: 0.033 ug.ml-1

c.Values expressed as Mean+SE and d. ND= Not detected;Values in the same column (mean±SE) bearing different superscripts vary significantly (P<0.05) in student’s‘t’ test

Comparison of total residue levels with prescribed MRLs

Tissue ECI (GOI)

EEC US-FDA Total Residues (PPB)

PPB PPB PPB Day 2 Day 3Muscle 100 100 100 70 (< MRL) (64.50+ 0.70) <MRL

Liver 200 200 300 250 (>MRL) (243.5+ 10.56) <MRL

Kidney 300 300 400 350 (>MRL) (347.0+ 1.41) <MRLNote: Total residues = Sum of Enrofloxacin and Ciprofloxacin residues in poultry meat

(Prakash et. al., 2016, KVAFSU project)

CAn§AiÉÆÃnPï£À Ew-«ÄwUÀ¼ÀÄLimitations of Antibiotics

• ¨ÉÃgÉ OµÀ¢üUÀ¼À ZÀ®£ÁªÀåªÀ¸ÉÛAiÀÄ°è ªÀåvÁå¸À(Impact on other drug metabolism)

• ¥Àj¸ÀgÀzÀ E¤ßvÀgÀ ¥ÁætÂUÀ½UÉ UÀAqÁAvÀgÀ(Risk of disease outbreak in other animal farms)

• ªÉÊgÁtÄ gÉÆÃUÀUÀ¼À°è CAn§AiÉÆÃnPïUÀ¼À ¥ÉÆÃ¯ÁUÀÄ«PÉ (Undue wastage of Antibitics during viral diseases)

• gÉÆÃUÀ ¤gÉÆÃzsÀPÀ ±ÀQÛAiÀÄ°è PÀÄApvÀ(Immuno deficiency)

• ¨É¼ÀªÀtÂUÉAiÀÄ°è PÀÄApvÀ(Impact on growth)

£ÁåAiÀÄ§zÀÞ OµÀzsÀ ¸ÀÆa§gÀºÀ JAzÀgÉÃ K£ÀÄ? What is Judicious Prescription?

PÉÆÃ½ OµÀzsÉÆÃ¥ÀZÀgÀzÀ ¸ÀªÀð¸ÁªÀiÁ£Àå vÀvÀéUÀ¼ÀÄ

Principals of medication in Poultry

1. ªÀÄÄAavÀªÁV E®èªÉÃ vÀqÀªÁV C£ÁgÉÆÃUÀåzÀ ¥ÀvÉÛ ?2. ¸ÀàµÀÖvÉ CxÁªÀ ÇÀàµÀÖvÉAiÀÄ wÃªÀæ vÉgÀ£ÁzÀ

¸ÉÆÃAPÀÄ?3. ¥ÁæxÀ«PÀªÁV AiÀiÁªÀ CAUÁUÀ ªÀÄÄPÁÌVzÉ.?4. ®¹PÉ ºÁQgÀÄªÀ CxÀªÁ ®¹PÉºÁQgÀzÀ PÉÆÃ½UÀ¼À

UÀÄA¥ÀÅ ?5. PÀgÀÄ½£À°è CAUÁ±À PÉÆ¼ÉvÀ, E®èèªÉÃ gÀPÀÛzÀ°è

£ÀAdÄ?6. ¤ÃgÀÄ CxÀªÁ ªÉÄÃ«£À°è OµÀzsÉÆÃ¥ÀZÀgÀ?7. ªÉÆmÉÖ CxÀªÁ ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ ?8. PÉÆÃ½ ªÉÄÃ«£À°è fÃªÁtÄ ¤gÉÆÃzsÀPÀUÀ¼À£ÀÄß

¸ÉÃj¹zÁÝgÉAiÉÄÃ? 9. PÉÆÃ½ ªÉÄÃ«£ÉÆA¢UÉ PÁQìÃrAiÀiÁ ¤gÉÆÃzsÀPÀ OµÀ¢ü?10. vÀ¯ÉaÃn ºÉÆA¢®èzÀ [Extra-label] OµÀ¢üAiÀÄ G¥ÀAiÉÆÃUÀªÀÅ C¤ªÁAiÀÄðªÉÃ?

zÉÃºÀzÀ°è OµÀ¢ü ZÀ®£ÉAiÀÄ QÃgÀÄ £ÉÆÃl

OµÉÆzsÀ¥ÀZÁgÀü »ÃjPÉÆ¼ÀÄîªÀÅzÀÄ ▼ «AUÀqÀ£ÉAiÀiÁUÀÄªÀÅzÀÄ ▼ gÀPÀÛ ¥ÀjZÀ®£ÉAiÀÄ°è OµÀ¢üAiÀÄ ¥ÀæªÀiÁt

▼ CAUÁUÀ zÀ°è «AUÀqÀ£É ▼ ¥ÀjªÀvÀð£É ▼ «¸Àdð£É

▼

OµÀ¢ü PÁAiÀÄð ¤ªÀð»¸ÀÄªÀ ¸ÀÜ¼ÀzÀ°è OµÀ¢üAiÀÄ ¥ÀæªÀiÁt

▼ OµÉÆzsÀ¥ÀZÁgÀüPÉÌ ¥ÀæwQæAiÉÄ CqÀØ¥ÀjuÁªÀÄü

CAUÁ±À zÀ°è G½PÉ

¸ÀÆPÁëätÄ ¤gÉÆÃzsÀPÀUÀ¼À ¸ÀzÀã¼ÀPÉ

(Judicious use of antibcterials)

¥sÉÇæÃ¥ÉÊ¯ÁåQÖÃPï OµÀ¢üUÀ¼ÀÄ (Prophylactic Use)

PÉÆÃ½UÀ¼À°è gÉÆÃUÀ PÁtÂ¸ÀÄªÀ ªÉÆzÀ¯ÉÃ, gÉÆÃUÀ vÀqÉUÀlÄÖ«PÉ G¥ÀAiÉÆÃV¸ÀÄªÀ OµÀ¢üUÀ¼ÀÄ GzÁ: [Chlortetracycline]

xÉÃgÁ¥ÀÇånPï OµÀ¢üUÀ¼ÀÄ (Therapeutic Use) PÉÆÃ½UÀ¼À°è gÉÆÃUÀ PÁtÂ¹zÀ £ÀAvÀgÀ aQvÉìUÁV

G¥ÀAiÉÆÃV¸ÀÄªÀ OµÀ¢üUÀ¼ÀÄ GzÁ: DåA¦ü¹°£ï [Ampicillin]

ªÉÄÃmÁ¦ü¯ÁåQìÃ¸ïì OµÀ¢üUÀ¼ÀÄ (Metaphylactic Use) MAzÀÄ PÉÆÃ½ ªÀÄAzÉAiÀÄ°è gÉÆÃUÀ PÁtÂ¹PÉÆAqÀØ°è, gÉÆÃUÀ E®èzÉÃ¬ÄgÀÄªÀ PÉÆÃ½ ªÀÄAzÉUÉ ªÀÄÄAeÁUÀævÉ¬ÄAzÁ G¥ÀAiÉÆÃV¸ÀÄªÀ OµÀ¢üUÀ¼ÀÄ.

GzÁ: mÉÊ¯ÉÆÃ¹£ï[ Tylosine]

±ÀÄzÀÞ gÀ¸ÁAiÀÄ¤PÀUÀ¼À£ÀÄß (Pure chemicals) G¥ÀAiÉÆÃV¸À¨ÁgÀzÀÄ. AiÀiÁªÀÅzÉÃ PÁgÀtPÀÆÌ F vÉgÀ£ÁzÀ

gÀ¸ÁAiÀÄ¤PÀUÀ¼À£ÀÄß aQvÉìUÁV E®èªÉÃ gÉÆÃUÀ vÀqÉUÀlÖ®Ä G¥ÀAiÉÆÃV¸À¨ÁgÀzÀÄ.

EzÀÄ OµÀ¢ü ºÉÆA¢gÀÄªÀ, ªÉí»PÀ¯ï, KQìÃ¦AiÀiÁAmï, DqÉÃ¹ªï UÀ¼À£ÀÄß ºÉÆA¢gÀÄªÀÅ¢®è.

±ÀÄzÀÞ gÀ¸ÁAiÀÄ¤PÀUÀ¼À£ÀÄß OµÀ¢üAiÀiÁV G¥ÀAiÉÆÃV¸ÀÄªÀÅzÀjAzÀ PÉÆÃ½UÀ¼À DgÉÆÃUÀåzÀ ªÉÄÃ¯É ¥ÀjuÁªÀÄªÀ£ÀÄß ©ÃgÀÄvÀÛªÉ, ºÁUÀÆ CAUÁ±À ²®ÄÌ ºÉZÀÄÑªÀ ¸ÁzsÀåvÉAiÀÄÄ ºÉaÑgÀÄvÀÛzÉ.

ºÁUÁV AiÀiÁªÁUÀ®Æ DAiÀiï.¦.,[I.P] AiÀÄÄ.J¸ï.¦[U.S.P] ªÀÄvÀÄÛ ©.¦ [B.P] UÉæÃqï OµÀ¢üUÀ¼À£ÉßÃ G¥ÀAiÉÆÃV¸À¨ÉÃPÀÄ.

PÉÆÃ½UÀ¼À°è OµÀ¢üUÀ¼À ¸ÀzÀã¼ÀPÉ ºÉÃUÉ?

1. OµÀ¢üUÀ¼À£ÀÄß «ªÉÃZÀ£É¬Ä®èzÉÃ (Indiscriminate) §¼À¸ÀPÀÆqÀzÀÄ

2. DåAn §AiÉÆÃnPï UÀ¼À£ÀÄß ¤UÀ¢üvÀ ¥ÀæªÀiÁtQÌAvÀ, PÀrªÉÄ ¥ÀæªÀiÁtzÀ°è ¥ÉÇæÃ§AiÉÆÃnPï UÀ¼ÁV E®èªÉÃ ¥ÉÇæÃ¥ÉÊ¯ÁåQÖÃPï UÀ¼ÁV §¼À¸ÀPÀÆqÀzÀÄ

3. ¤UÀ¢ü¥Àr¹zÀ ¥ÀæªÀiÁtQÌAvÀ PÀrªÉÄ/ ºÉZÀÄÑ ¥ÀæªÀiÁtzÀ°è OµÀ¢ü PÉÆqÀ¨ÁgÀzÀÄ

4. ªÀiÁA¸ÀzÀ ªÀÄvÀÄÛ ªÉÆmÉÖ PÉÆÃ½UÀ½UÉ ¤UÀ¢ü¥Àr¹zÀ OµÀ¢üUÀ¼À£ÀÄß CzÀ®Ä §zÀ¯ÁV¸À¨ÉÃr

5. ªÉÊeÁ¤PÀ ªÀiÁ»w ºÉÆAzÀzÉÃ, ¥ÀzÉÃ ¥ÀzÉÃ OµÀ¢üAiÀÄ£ÀÄß §zÀ¯Á¬Ä¸ÀPÀÆqÀzÀÄ

6. eÁ£ÀÄªÁgÀÄUÀ½UÉ «Ä¸À°ÃlÖ OµÀzsÀUÀ¼À£ÀÄß PÉÆÃ½UÀ¼À°è G¥ÀAiÉÆÃV¸ÀPÀÆqÀzÀÄ

7. ªÀiÁgÀÄPÀmÉÖ¬ÄAzÀ »A¥ÀqÉzÀ OµÀ¢üAiÀÄ£ÀÄß G¥ÀAiÉÆÃV¸ÀzÉÃ¬ÄgÀÄªÀÅzÀÄ.

PÁ¯Á²ævÀ ªÀÄvÀÄÛ ¥ÀæªÀiÁuÁ²ævÀ fÃªÁtÄ ¤gÉÆÃzsÀPÀUÀ¼À DAiÉÄÌ

PÁ¯Á²ævÀ fÃªÁtÄ ¤gÉÆÃzsÀPÀUÀ¼ÀÄ

Need to maintain constant MIC ¥É¤ì°£ïì ¸ÉÃ¥sÁ¯ÉÆÃ¸ÉÆàÃj£ïì ªÀiÁåPÉÆæÃ°qïì(mÉÊ¯É

ÆÃ¹£ï)

¥ÀæªÀiÁuÁ²ævÀ fÃªÁtÄ ¤gÉÆÃzsÀPÀUÀ¼ÀÄ

Possess post-antibiotic effect CªÉÄÊ£ÉÆÃUÉèöÊPÉÆÃ¸

ÉÊqïì ¥ÉÇèÃgÉÆÃQé£Á¯ÉÆÃ£ï

ì mÉÃmÁæ¸ÉÊQèÃ£ïì £ÉÊmÉÆæÃ«ÄqÁeÉÆÃ¯ïì ¥ÉÇèÃgÉÆÃªÀÄÄn°£ïì

(mÁAiÀÄªÀÄÄ°£ïì) ¸ÉÃ¥sÁªÉÄÊ¹£ïì

¨ÁåQÖÃjAiÀiÁ ¨É¼ÀªÀtÂUÉ ¤ªÁgÀPÀUÀ¼ÀÄ vs

¨ÁåQÖÃjAiÀiÁ£Á±ÀPÀUÀ¼ÀÄ?¨ÁåQÖÃjAiÀiÁ ¨É¼ÀªÀtÂUÉ ¤ªÁgÀPÀ UÀ¼ÀÄ

¨ÁåQÖÃjAiÀiÁ £Á±ÀPÀUÀ¼ÀÄ

¥ÉÇèÃgÉÆÃªÀÄÄn°£ïì

(mÁAiÀÄªÀÄÄ°£ïì)

¥ÉÇèÃgÉÆÃQé£Á¯ÉÆÃ£ïì

ªÀiÁåPÉÆæÃ°qïì(mÉÊ

¯ÉÆÃ¹£ï)

CªÉÄÊ£ÉÆÃUÉèöÊPÉÆÃ¸ÉÊqïì

°APÉÆÃ¸ÀªÉÄÊqïì ¥É¤ì°£ïì

mÉÃmÁæ¸ÉÊQèÃ£ïì

¸ÉÃ¥sÁ¯ÉÆÃ¸ÉÆàÃj£ïì

£ÉÊmÉÆæÃ¥ÉÇÃgÁeÉÆÃ£ïì

¸À¯Áá£ÀªÉÄÊqï+mÉæöÊ«ÄxÉÆ¦æªÀiï

¸ÀÆPÁë÷ätÄ ¤gÉÆÃzsÀPÀUÀ¼À£ÀÄß MUÀÆÎr¹

G¥ÀAiÉÆÃV¹ªÀÅzÀÄ MUÀÆÎr¸ÀÄ«PÉ ¥ÀjuÁª

ÀÄUÀªÀÄ¤¹/µÀgÁ

¨ÁåQÖÃjAiÀiÁ ¨É¼ÀªÀtÂUÉ ¤ªÁgÀPÀ Û[PÉÆÃ½ DºÁgÀzÀ°è] + ¨ÁåQÖÃjAiÀiÁ£Á±ÀPÀUÀ¼ÀÄ [aQvÉìUÁV;During GI-infection]

vÀ¢égÀÄzÀÝ

zÀÆgÀ«j¹

¨ÁåQÖÃjAiÀiÁ£Á±ÀPÀUÀ¼ÀÄ[ZÀÄZÀÄÑªÀÄzÀÄÝUÀ¼ÀÄ]+ ¨ÁåQÖÃjAiÀiÁ ¨É¼ÀªÀtÂUÉ ¤ªÁgÀPÀ [PÉÆÃ½ ¤ÃgÀÄ ªÀÄvÀÄÛ DºÁgÀzÀ°]

vÀ¢égÀÄzÀÝ

zÀÆgÀ«j¹

¥É¤ì°£ïì(Old generation )+¸ÉÃ¥sÁ¯ÉÆÃ¸ÉÆàÃj£ïì I/ IIgen.

¥ÀæwgÉÆzsÀ±ÀQÛ zÀªÀÄ£À

zÀÆgÀ«j¹

©ÃmÁ ¯ÁåPÁÖªÀiïì + Qé£Á¯ÉÆÃ£ïì ¸ÀAAiÉÆÃfvÀ

GvÀÛªÀÄ/ AiÉÆÃUÀå

CªÉÄÊ£ÉÆÃUÉèöÊPÉÆÃ¸ÉÊqïì + Qé£Á¯ÉÆÃ£ïì

¸ÀAAiÉÆÃfvÀ

GvÀÛªÀÄ/ AiÉÆÃUÀå , DzÀgÉÃ eÁUÀgÀÆPÀvÉ¬ÄAzÀ §¼À¸À¨ÉÃPÀÄ

£ÉÊmÉÆæÃ¥ÉÇÃgÁeÉÆÃ£ïì * + Qé£Á¯ÉÆÃ£ïì

vÀ¢égÀÄzÀÝ

zÀÆgÀ«j¹

PÉÆèÃgÁA¦ü¤PÁ¯ï* + ªÀiÁåPÉÆæÃ°qïì GzÁ: mÉÊ¯ÉÆÃ¹£ï

vÀ¢égÀÄzÀÝ

¸ÀvÀvÀ zÀÆgÀ«j¹

CªÉÄÊ£ÉÆÃUÉèöÊPÉÆÃ¸ÉÊqï + PÉÆèÃgÁA¦ü¤PÁ¯ï*

vÀ¢égÀÄzÀÝ

¸ÀvÀvÀ zÀÆgÀ«j¹

PÉÆÃ½ ªÀAiÀÄ¸ÀÄì Consider the age [Guo, et.al., 2013;PLoS ONE]

7. ªÀÄ£ÀÄµÀågÀÄ ªÀÄvÀÄÛ PÉÆÃ½UÀ¼À°è G¥ÀAiÉÆÃUÀ ªÀÄvÀÄÛ CªÀÅUÀ¼À ¥ÁæªÀÄÄRåvÉAiÀÄ DzsÁgÀzÀ ªÉÄÃ¯É ¸ÀÆPÁë÷ätÄ ¤gÉÆÃzsÀPÀUÀ¼À DAiÉÄÌ¸ÀÆPÁë÷ät

Ä ¤gÉÆÃzsÀP

ÀUÀ¼À ªÀUÀð

G¥ÀAiÉÆÃUÀzÀ DzÀåvÉ GzÁºÀgÀuÉ

ªÀUÀð I(Class I)(¥ÀæzsÁ£À C¥ÁAiÀÄ)

¥ÀæªÀÄÄRªÁV ªÀÄ£ÀÄµÀå ªÉÊzÀåQÃAiÀÄ ±Á¸ÀÛçzÀ°è; G¥ÀAiÉÆÃUÀ PÉÆÃ½UÀ¼À°è aQvÉìUÁV PÁ¬ÄÝj¸À§ºÀÄzÀÄ

¥ÉÇèÃgÉÆÃQé£Á¯ÉÆÃ£ïì: K£ÉÆæÃ¥sÉèPÁìQì£ï, ¹¥ÉÇæÃ¥sÉèPÁìQì£ï, ¥sÉ¥sÉèPÁìQì£ï, M¥sÉèPÁìQì£ï,¯ÉªÉÇÃ¥sÉèPÁìQì£ï, ¸Áàgï¥sÉèPÁìQì£ï.

ªÀUÀð II(Class II)(ªÀiÁzsÀå«ÄPÀ C¥ÁAiÀÄ)

ªÀÄ£ÀÄµÀå ªÉÊzÀåQÃAiÀÄ ±Á¸ÀÛçzÀ°è ªÀiÁzsÀå«ÄPÀªÁV G¥ÀAiÉÆÃUÀ PÉÆÃ½UÀ¼À°è aQvÉìUÁV ªÀiÁzsÀå«ÄPÀªÁV

JjÃvÉÆæÃªÉÄÊ¹£ï, ¥É¤ì°£ïì, dAmÁªÉÄÊ¹£ï, ¸ÉÃ¦üÖAiÉÆÃ¥sïgï,¸À¯Áá£ÁªÉÄÊqïì ªÀÄvÀÄÛ mÉmÁæ¸ÉÊQèÃ£ïì.

ªÀUÀð III(PÀrªÉÄ C¥ÁAiÀÄ)Class III

ªÀÄ£ÀÄµÀå ªÉÊzÀåQÃAiÀÄ ±Á¸ÀÛçzÀ°è G¥ÀAiÉÆÃUÀ PÀrªÉÄ, PÉÆÃ½UÀ¼À°è aQvÉìUÁV ªÀiÁzsÀå«ÄPÀªÁV G¥ÀAiÉÆÃUÀ (Majority of them has low per oral bioavailability)

¨Áå¹mÉæÃ¹£ï, ¸ÉÖçÃ¥sÉÇÖÃªÉÄÊ¹£ï, mÉÊ¯ÉÆÃ¹£ïì, ¸ÉàÃQÖ£ÉÆÃªÉÄÊ¹£ï, ¤AiÉÆÃªÉÄÊ¹£ï ªÀÄvÀÄÛ mÁAiÀÄªÀÄÄ°£ï

Farm history and/ or in vitro sensitivity Clinical judgment Use labeled directions before opt for extra-label Narrow spectrum antibiotic, if pathogen is known

PÉÆÃ½ ¸ÁPÁuÉAiÀÄ EwºÁ¸À ªÀÄvÀÄÛ ¸ÀÆPÁë÷ätÄ ¤gÉÆÃzsÀPÀUÀ¼À DzsÀåvÉ

PÁ¬Ä¯É DAiÉÄÌAiÀÄ DzsÀåvÉ

¸ÀÆPÁë÷ätÄ ¤gÉÆÃzsÀPÉÃvÀgÀ ºÀ¸ÀÛPÉëÃ¥À

PÉÆÃ°¨Áå¹¯ÉÆÃ¹¸ï{Septicemia}

Class III Class II Class I

CªÉÆÃ¤AiÀiÁ/zsÀÆ½£À ªÀÄlÖªÀ£ÀÄß PÀrªÉÄ ªÀiÁqÀÄªÀÅzÀÄ,UÁ½QAr ºÉZÀÄÑªÀiÁqÀÄªÀÅzÀÄ, ºÉZÀÄÑ ZÀ½/±ÁR¢AzÀ zÀÆgÀ«gÀÄ¸ÀÄªÀÅzÀÄ, ºÉPÉÌAiÀÄ vÉÃªÁA±À PÀrvÀUÉÆ½¸ÀÄªÀÅzÀÄ. ªÀiÁågÉÃPïì ¤AiÀÄAvÀætzÀ°è¬ÄqÀÄªÀÅzÀÄ.

¥sÉÇÃªïè PÁ¯ÉgÀ{Septcemia, lung infection, menigistis, arthritis,cellulitis}

Class II Class I Class III {Extra-label}

PÀpt §AiÉÆÃ¸ÉPÀÆåjn PÀæªÀÄUÀ¼ÀÄ, ¸ÀwÛgÀÄªÀ PÉÆÃ½UÀ¼À£ÀÄß PÀæªÀÄªÁV «¤AiÉÆÃUÀ ªÀiÁqÀÄªÀÅzÀÄ.

£ÉPÉÆæÃnPï JAngÉÊn¸ï {Acute to chronic enteritis with necrosis of upper SI}

Class III Class II PÁQìrAiÀiÁ ¤gÉÆÃzsÀPÀUÀ¼À PÁAiÀÄðPÀæªÀÄ «ªÀÄ²ð¹ £ÀAvÀgÀ PÉÆÃ½ ªÀ¸ÀwAiÀÄ£ÀÄß ¸ÉÆÃAPÀÄ ¤ªÁgÀuÉ ªÀiÁqÀÄªÀÅzÀÄ.

ªÉÄÊPÉÆÃ¥sÁè¸Áä{M.gallisepticum}

Class III Tylosin/ Tiamutin Class II Tetracyclines

PÉÆÃ½UÀ¼À°è EgÀÄªÀ PÁ¬Ä¯ÉUÉ aQvÉì ¤ÃqÀÄªÀÅzÀÄ; PÀpt §AiÉÆÃ¸ÉPÀÆåjn PÀæªÀÄUÀ¼ÀÄ. Class I [India, South Asia] Class II [Tetracyclins & Erythromycin, if M. synoviae]

¸Á¯Áä£É¯ÉÆèÃ¹¸ï{Brooder house Eggs, Later Poults}

Class III limited basis Class II limited basis May require Extra-label

¸ÀAvÁ£ÉÆÃvÁàzÀ£ÉUÁV Ej¹zÀ ªÀÄAzÉAiÀÄ gÀPÀÛ ¥ÀjÃPÉë ªÀiÁr¸ÀÄªÀÅzÀÄ; £ÀAvÀgÀ PÁåjAiÀÄgï PÉÆÃ½UÀ¼À£ÀÄß ªÀzsÉ ªÀiÁqÀÄªÀÅzÀÄ [Prevent vertical transmission via eggs]

¸ÁÖ¥sÁå¯ÉÆÃPÁPÀ¸ï{Hock &Footpad,Swollen head-celllulitis; Osteomyelitis}

Class II Penicillins, Cephalexin, Erythromycin

gÉÆÃUÀzÀ ªÀÄlÖªÀ£ÀÄß ¥ÀjÃQë £ÀAvÀgÀ OµÀzsÉÆÃ¥ÀZÀgÀ ªÀiÁqÀÄªÀÅzÀÄ. Identify the predisposing factors; Upper respiratory infection ?

fÃªÀ ¸ÀÄgÀQëvÀ PÀæªÀÄUÀ¼ÀÄ: ¤Ãj£À ±ÀÄavÀé

OµÀ¢üAiÀÄ ºÉ¸ÀgÀÄ ¤Ãj£À ±ÀÄavÀéPÁÌV

¸ÉÆÃAPÀÄ vÀqÉUÀlÄÖªÀÅzÀPÁÌV

PÉÆèÃj£ï qÉÊDPÉìöÊqï 1«Ä.°Ã / °Ã ¤ÃjUÉ 20 «Ä.°Ã / °Ã. ¤ÃjUÉ

DQìqÉÊ¹AUï KeÉAmïì + DUÁåð¤Pï Då¹qï + ¸À¥sÉðÃPÉÖAmïì

1 UÁæA / °Ã ¤ÃjUÉ 4 UÁæA / °Ã. ¤ÃjUÉ During N.D & I.B.D outbreak

DAiÉÆÃr£ï ±ÉÃ-0.01, 1«Ä.°Ã / 10°Ã ¤ÃjUÉ

±ÉÃ 0.1, 10«Ä.°Ã /1°Ã. ¤ÃjUÉ

¥sÀgï Då¹nPï Då¹qï +H2O2 + DUÁåð¤Pï Då¹qï

1-2 «Ä.°Ã / 20°Ã ¤ÃjUÉ

4 «Ä.°Ã / °Ã. ¤ÃjUÉ

¨ÉÃeÉÊ¯ï PÉÆÃ¤AiÀÄªÀiï PÉÆèÃgÉÊqï

1 «Ä.°Ã / 20°Ã ¤ÃjUÉ 1 «Ä.°Ã / °Ã. ¨ÉZÀÑ£ÉAiÀÄ ¤ÃjUÉ [For cleaning table Eggs]

fÃªÀ ¸ÀÄgÀQëvÀ PÀæªÀÄUÀ¼ÀÄ- ¸ÉÆÃAPÀÄ ¤ªÁgÀPÀUÀ¼À ¸ÀzÀã¼ÀPÉ

¸ÉÆÃAPÀÄ¤ªÁgÀPÀ

¨ÁåQÖÃj¸ÉÊqÀ¯ï

¸ÉÆàÃj¸ÉÊqÀ¯ï

ªÉÊj¸ÉÊqÀ¯ï

¥sÀAV¸ÉÊqÀ¯ï

¥ÁågÁ¸ÉÊn¸ÉÊqÀ¯ï

C¯ÉÆÌÃºÀ¯ï Alcohol

++++ - ++ + -

ºÁå¯ÉÆÃf£ïìIodophores; Hypochlorins

++++ - ++ + -

PÀÆå. J. ¹/ Q.A.C ++++ - + + -

¦ü£Á°Pïì / Phenol ++++ - - - -

PÉÆÃ¯ÁmÁ¸ïð ++++ - - -

D°ØºÉÊqïì/ HCHO ++++ + ++ ++ +

DQìqÉÊ¹AUï KeÉAmïìKMnO4 & H2O2

+++ - - - -

ºÁåZÀjÃ ¸ÀÄgÀQëvÀ PÀæªÀÄUÀ¼ÀÄ- ªÉÆmÉÖUÀ½UÉ aQvÉì

Egg Dipping in Antimicrobial Solution Gentamicin: 0.5g.L-1 ; Tylosin 1g.L-11g /Lt

ªÉÆmÉÖUÀ¼ÀÄ

37-380¹ UÉ E£ÀÆÌ÷å¨ÉÃl¤èð ElÄÖ ¨ÉZÀÑUÉ

ªÀiÁqÀ¨ÉÃPÀÄ

[mÉÊ¯ÉÆÃ¹£ï/JjxÉÆæÃªÉÄÊ¹£ï/dAmÁªÉÄÊ¹£ï]

zÀæªÀzÀ ±ÁR 1.7 – 4.40¹ gÀ¶ÖgÀ¨ÉÃPÀÄ

ªÉÆmÉÖUÀ¼À£ÀÄß 0.04% - 0.1% ¸ÀÆPÁë÷ätÄfÃ«¤gÉÆÃzsÀPÀ zÀæªÀzÉÆA¢UÉ

10 jAzÀ 30 ¤. ªÀÄÄ¼ÀÄV¹qÀÄªÀÅzÀÄ

ºÁUÁV ªÉÆmÉÖAiÀÄ ªÉÄÃ°gÀÄªÀ gÀAzsÀæUÀ¼À ªÀÄÆ®PÀ ¸ÀÆPÁë÷ätÄfÃ«¤gÉÆÃzsÀPÀªÀÅ ¥ÀæªÉÃ²¸ÀÄªÀÅzÀjAzÀ ªÀÄjUÀ½UÉ ªÀUÁðªÁUÀÄªÀ ¸ÉÆÃAPÀ£ÀÄß

¥ÀjuÁªÀÄPÁjAiÀiÁV vÀqÉUÀlÖ§ºÀÄzÀÄ

9. OµÀzsÉÆÃ¥ÀZÀgÀªÀ£ÀÄß vÁAwæPÀªÁV ¥ÀæªÀiÁt§zÀÝUÉÆ½¸ÀÄªÀÅzÀÄ

[Tiamulin in water vs feed (~ 12.5mg.kg-1 ) to prevent vertical transmission]

David G.S Burch, 2009

DzsÀÄ¤PÀ ¸ÀÆPÁë÷ätÄ ¤gÉÆÃzsÀPÀUÀ¼À DAiÉÄÌ……

¸É¥sÉÇÃ¯ÉÆÃ¸ÉÆáj£ïì First generation: ¨Á¬Ä ªÀÄÆ®PÀ: ¸É¥sÁ¯ÉQì£ï• ¥ÀæªÀÄÄRªÁV Gram +ve; weak: Gram -ve • ªÀÄÄRåªÁV ©ÃmÁ ¯ÁåPÁÖªÉÄÃ¸ï +ve; S.aureaus • PÁæ¸ï gÉ¹¸ÉÖAmï - ¥É¤ì°£ïì( Ampicillin, Amoxicillin)

Second generation: ¨Á¬Ä ªÀÄÆ®PÀ: ¸É¥sÁPÉÆèÃgï• CªÀ±ÀåªÁV Gram -ve; weak acticity:Gram +ve • gÉ¹¸ÉÖAmï- ©ÃmÁ ¯ÁåPÁÖªÉÄÃ¸ï Third generation: ¨Á¬Ä ªÀÄÆ®PÀ: ¸É¦üÃPÉìöÊªÀiï,

ZÀÄZÀÄÑªÀÄzÀÄÝ: ¸É¦üÖAiÉÆÃ¥sïgï • ¥ÀæªÀÄÄRªÁV- JAnÃgÉÆÃ¨ÁåQÖÃjAiÉÄÃ¹• ºÉaÑzÀ ZÀlÄªÀnPÉ against Gram-ve ; Active against

anaerobes • gÉ¹¸ÉÖAmï- ©ÃmÁ ¯ÁåPÁÖªÉÄÃ¸ï Fourth generation: ¸ÉÃ¦ü¥sÉÊªÀiï• PÉÆÃ½UÀ¼À°è G¥ÀAiÉÆÃV¸ÀÄªÀ §UÉÎ

ªÀiÁ»w¬Ä®è. • ºÉaÑzÀ ZÀlÄªÀnPÉ against Gram-ve and anaerobes• Highly resistant to ß-lactamase

PÉÆÃ½UÀ¼À°è ªÀiÁåPÉÆæÃ°qÀìUÀ¼À £ÁåAiÀÄ§zÀÞ G¥ÀAiÉÆÃUÀ

JjvÉÆæÃªÉÄÊ¹£ï- mÉÊ¯ÉÆÃ¹£ï-¸ÉáöÊgÁªÉÄÊ¹£ï- n°äPÉÆÃ¹£ï

Selection of

ªÀ¸ÀÄÛ«£À ªÀÄÆ®, ±Áé¸ÀPÉÆÃ±ÀzÀ°è OµÀ¢üAiÀÄ ¥ÀæªÀiÁt (Acidic-trapping)

PÀgÀÄ¼ÀÄ AiÀÄPÀÈvï£À ¸ÉÊQèAUï : Concentrate in bile PÉÆÃ±ÀzÉÆ¼ÀV£À ¥ÀæªÀiÁt > 20 times Plasma 75% ¥sÁè¸Áä ¥ÉÇæÃn£ï §AzsÀ ±Áé¸ÀPÉÆÃ±À- UÁ½ aÃ®-AiÀÄPÀÈvï- ªÀÄÆvÀæ¦AqÀ-

¥ÀÇègÁ- D¸ÉÊnPï zÀæªÀ- ªÉÄzÀÄ CAUÁA±ÀUÀ¼ÀÄ ¥É¤ì°£ïUÉ gÉ¹ìmÉAmï EzÀÝ°è Gram +ve and Mycoplasma/Chlymydia ¸ÉÆÃAPÀÄ EzÁÝUÀ ºÉZÀÄÑ ºÉZÀÄÑ G¥ÀAiÉÆÃV¹zÁUÀ - Cholistatic hepatitis ? PÀgÀ¼ÀÄ ªÀÇåºÀ £À ªÉÃUÀ eÁ¹ÛAiÀiÁUÀÄªÀÅzÀÄ/

vÉÆAzÀgÉAiÀiÁUÀÄªÀÅzÀÄ QÃªÀÅ vÀÄA©zÀ/ PÉÆ¼ÉvÀ fÃuÁðAUÀzÀ°èè OµÀ¢üAiÀÄ

UÀÄt PÀrªÉÄAiÀiÁUÀÄªÀÅzÀÄ

PÀ¤µÀ× ¥ÀPÀë ¸ÉÆÃAPÀÄ ¦ÃrvÀ CAUÁUÀ¼À DzsÁgÀzÀ ªÉÄÃ¯É OµÀ¢üUÀ¼À DAiÉÄÌ

Organ directed prescription policy ¸ÉÆÃAPÀÄ ¦ÃrvÀ CAUÁUÀ¼ÀÄ OµÀ¢üUÀ¼À DAiÉÄÌ

±Áé¸ÀPÉÆÃ±À- UÁ½ aÃ®- UÀAl®Ä

gÉ¹ágÉÃmÁj ¥sÀÇègÉÆÃQé£Á¯ÉÆÃ£ïì n®ÆäPÉÆÃ¹£ï, JjvÉÆæÃªÉÄÊ¹£ï

ªÀÄÆvÀæ¦AqÀ ¥É¤ì°£ïì ,mÉmÁæ¸ÉÊQèÃ£ïì ,J¥sÁæªÉÄÊ¹£ï

AiÀÄPÀÈvï ¥É¤ì°£ïì ,mÉmÁæ¸ÉÊQèÃ£ïì ,J¥sÁæªÉÄÊ¹£ï ªÀÄvÀÄÛ ¸ÉÃ¥sÁ¯ÉÆÃ¸ÉÆàÃj£ïì

doÀgÀ- PÀgÀ¼ÀÄ ªÀÇåºÀ DªÉÄÊ£ÉÆÃ¸ÉÊQèÃmÁ¯ïì[¸ÉàÃQÖ£ÉÆÃªÉÄÊ¹£ï] J¥sÁæªÉÄÊ¹£ï, DªÉÄÊ£ÉÆÃUÉèöÊPÉÆ¸ÉÊqïì: ¤ÃAiÉÆªÉÄÊ¹£ï

¦vÀÛ gÀ¸À/ doÀgÀ- PÀgÀ¼ÀÄ ªÀÇåºÀ

¥sÉ¤PÁ¯ïì*

G½zÀ E¤ßvÀgÀ CAUÁUÀ¼ÀÄ ¸À¯Áá£ÁªÉÄÊqïì + mÉæöÊ«ÄxÉÆÃ¦üæªÀiï ¥sÀÇègÉÆÃQé£Á¯ÉÆÃ£ïì ªÀiÁåPÉÆæÃ°qï ì[mÉÊ¯ÉÆÃ¹£ï, ¸ÉàöÊgÉÆÃªÉÄÊ¹£ï] °APÉÆÃªÉÄÊ¹£ï

WTO/ GATS :148 member countries ,160 Services

WTO Sanitary & Phytosanitory Measures(SPS) FAO / WHO IPPC: Int.Plant Protection Commission CAC : Codex Alimentarius Commission Codex committee n Food hygiene/ Food additives/Pesticide residues/ Codex committee on residues of Veterinary drugs in foods (CCRVDF)

¸ÀÆPÁë÷ätÄ ¤gÉÆÃzsÀPÀUÀ¼À CªÀgÉÆÃzsÀ ªÀÄvÀÄÛ CzÀgÀ ªÀUÁðªÀuÉ

[Antibiotic Resistance and its Transmission]

UÀjµÀ× OµÀzsÀ ±ÉÃµÀ/²°Ì£À ªÀÄlÖ Maximum Residual Level (MRL)

• MRL: Country specific, hence trade disputes• MRL: Species - Tissue - Commodity specific • MRL: US FDA, EU, Japan, Australia, CAC -MRL

Codex Alimentarius Commission(CAC)

• CCRVDF: Codex Committee on residues of veterinary drugs in foods• CCRFFP: Codex Committee on residues in fish and fish products• Regional: FAO/WHO Codex Committee for South Asia• Ad hoc: Ad hoc task force on animal feeds

• Official : Lowest between bacteriological & toxicological MRL MRL

PÉÆÃ½UÀ¼À°è OµÀ¢ü »A¥ÀqÉzÀ £ÀAvÀgÀ CAUÁ±ÀzÀ°ègÀÄªÀ ¥ÀæªÀiÁt

Tissue concentrations (μg.g-1) in Chickens After Drug WithdrawalCAUÁUÀ OµÀ¢ü

»A¥ÀqÉzÀ £ÀAvÀgÀ ¢£ÀUÀ¼À°èNo of days after Drug Withdrawal

mÉÃmÁæ¸ÉÊQèÃ£ïì

qÁQì¸ÉÊQèÃ£ïì

£Ágï¥sÉèÃPÁìQì£ï(M1:-oxo/ M2: desethyl)

J£ïgÉÆÃ¥sÉèPÁìQì£ï M1:¹¥ÉÇæÃ¥sÉèPÁìQì£ï

ªÀiÁA¸À RAqÀUÀ¼

ÀÄ

1356

12

0.230.150.031--

1.180.260.06--

0.29(0.21/ 0.54)-0.21(0.22/0.32)-ND (0.008/0.05)

0.54 (0.65)--ND (1.18)ND (0.010)

AiÀÄPÀÈvï 1356

12

0.300.180.050--

0.900.540.12--

0.65 (0.32/0.93)-0.24(0.16/0.77)-0.05(.034/0.10)

0.99(0.96)--0.41(1.37)0.025(0.071)

ªÀÄÆvÀæ¦AqÀ

1356

12

0.430.210.13--

1.920.930.17--

0.92(0.24/1.09)-0.39(0.12/0.67)-0.05(0.04/0.07)

0.91(3.02)--0.32(0.90)

PÉÆ§Äâ 1356

12

----

----

0.37(0.110.36)-0.20(0.08/0.31)-0.05(0.022/0.06)

0.35(0.32)--ND(ND)ND(ND)

Anadon et.al. Anadon.A, and Martinez-Larranaga, M.R : 1999:Livestock Prod. Science, 59:183-198)

1993 In: Euro Residues

1994 in Avain Pathology

1992 in Am .J Vet .Res 1995 in Am .J Vet. R

¥ÉÇæÃ§AiÉÆÃnPï UÀ¼À ¸ÀÄgÀQëvÀ G¥ÀAiÉÆÃUÀ

Safe Nutritional Use of Antimicrobials… PÉÆÃ½ DºÁgÀzÀ°è

¥ÉÇæÃ§AiÉÆÃnPïUÀ¼À G¥ÀAiÉÆÃUÀzÀ ªÀÄlÖ

»AvÉUÉAiÀÄÄªÀ PÁ¯ÁªÀ¢ü

Withdrawal Period

fÃAPï ¨Áå¹ìmÉæÃ¹£ï/Bacitracin 4-50g.ton-1 [Zinc or methylene disalicyate]

‘5’¢£ÀUÀ¼ÀÄ/days

PPÉÆèÃgï mÉÃmÁæ¸ÉÊQèÃ£ïì /Chlortetracycline 5-50g.ton-1

‘0’ ¢£ÀUÀ¼ÀÄ/da

ys°APÉÆÃªÉÄÊ¹£ï/ Lincomycin 2-4g.ton-1

‘0’¢£ÀUÀ¼ÀÄ/

daysDQìmÉÃmÁæ¸ÉÊQèÃ£ïì / Oxytetracycline 5-100g.ton-1


ysgÉÆÃPÁì¸ÉÆðÃ£ï/ Roxarsone 0.0025-0.005 %


ys«fðÃ¤AiÀiÁªÉÄÊ¹£ï/ Virginiamycin 5-20g.ton-1

0 ¢£ÀUÀ¼ÀÄ/da

ysmÉÊ¯ÉÆÃ¹£ï/ Tylosin 4-50g.ton-1


ys¥sÀÇgÁeÉÆÃ¯ïqÁ£ï Furazolidone* 0.00083-0.0011%EU, US FDA & Codex MRL =‘0’


ysD¸Éð¯ï ¤Pï C¹qï/Arsanilic acid¸ÉÆÃrAiÀÄªÀiïá D¸Éð¤¯Áåmï/Sodium arsanilate 0.01%


ys

E½PÉ PÀæªÀiÁAPÀzÀ¼À°è PÉÆÃ½UÀ¼À°è PÉ®ªÉÇAzÀÄ OµÀ¢üUÀ¼À CAUÁ±À ²®ÄÌ ¥ÀæªÀiÁt

Ranking of tissue residues certain drugs in decreasing order in poultry

AiÀÄPÀÈvï

ªÀÄÆvÀæ¦AqÀ

ªÀiÁA¸À RAqÀUÀ¼ÀÄ

ZÀªÀÄð + PÉÆ§Äâ

PÉÆ§Äâ

qÉÃPÉÆQéÃ£ÉÃmï

3 2 4 1 -

qÉÊPÁèdÆj¯ï 1 2 3 4 -qÁQì¸ÉÊQèÃ£ï 2 1 3 - -

¥ÉÇèÃgï¥sÉ¤PÁ¯ï

1 2 4 3 -

ºÁå¯ÉÆÃ¥ÀÇf£ÉÆÃ£ï

1 2 4 3 -

¯Áå¸Á¯ÉÆÃ¹qï 1 3 4 2 -°APÉÆÃªÉÄÊ¹£ï 1 2 - 3 -

£ÁgÀ¹£ï 1 4 5 2 2ªÀÄqÀÄgÁªÉÄÊ¹

Ã£ï1 - 2 - -

ªÉÆÃ£É¤ì£ï 1 3 4 2 -gÉÆÃ¨ÉÃ¤r£ï 1 3 4 2 -

¸Áå°£ÉÆÃªÉÄÊ¹£ï

1 3 3 - 2

¸ÉªÀiï qÀÆågÁªÉÄÊ¹£ï

1 2 3 5 4

¸ÉàÃQÖ£ÉÆÃªÉÄÊ¹£ï

3 2 4 1 -

mÁAiÀiÁªÀÄÄ°£ï 1 - 3 2 -nÃ®ÆäPÉÆÃ¹£ï 1 2 3 3 3

mÉæöÊªÉÄÃvÉÆÃ¦æªÀiï

Note: 1>2> 3> 4 > 5

1 2 3 - 4

K¥ÁæªÉÄÊ¹£ïvÁeÁ PÉÆÃ½ ªÀiÁA¸À ªÀÄvÀÄÛ ªÀiÁA¸ÀzÀ G¥À GvÀà£ÀßUÀ¼À°è CAUÁ±À

²®ÄÌ vÀqÉUÀlÄÖªÀ°è ÷¨sÁgÀvÀ ¸ÀPÁðgÀzÀ ¤§AzsÀ£ÉUÀ¼ÀÄEIC: Regulatory programme for Control of Residues in Fresh Poultry meat & Poultry meat products (For export to Non-EU countries (in units approved for export to all countries except EU dt. 14.3.2012

Set/Group

Substances to be monitored

Compound /marker residue Level of action above which deemed non- compliance MRPL/ MRL [μg.kg-1]

Set5 /A6 PÉÆèÃgÁA¥sÉí¤PÁ¯ï

Chloramphenicol 0.3μg.kg-1

£ÉÊmÉÆæÃ¥ÀÇågÁ£ÁÖ¬Ä£ï ªÉÄÃmÁ¨ÉÆÃ¯ÁAiÀiïÖ¥ÀÇågÁ¯ÁÖqÉÆ£ï ªÉÄÃmÁ¨ÉÆÃ¯ÁAiÀiïÖ

£ÉÊmÉÆæÃ¥ÀÇågÁ£ÁÖ¬Ä£ï ªÉÄÃmÁ¨ÉÆÃ¯ÁAiÀiïÖ¥ÀÇågÁ¯ÁÖqÉÆ£ï ªÉÄÃmÁ¨ÉÆÃ¯ÁAiÀiïÖ

Aminohydantoin (AHD) 3-amino-5-morpholinomethyl -2-

oxazolidinone (AMOZ) Amino-oxazolidinone (AOZ) Semicarbazide (SEM)

1.0μg.kg-1

1.0μg.kg-1

1.0μg.kg-1

1.0μg.kg-1

£ÉÊmÉÆæÃ«ÄÃqÁeÉÆìÃ¯ïì

Dimetridazole Ipronidazole Metronidazole Ronidazole

1.0μg.kg-1

1.0μg.kg-1

1.0μg.kg-1

1.0μg.kg-1

Set-6/B1 DåAn¨ÁåQÖÃjAiÀiÁUÀ¼ÀÄ

Amoxycillin Difloxacin

Doxycycline

Enrofloxacin (Sum of enrofloxacin and ciprofloxacin)

Muscle/Fat/Liver/Kidney: 50 Muscle:300, Fat:400, Liver: 1900, Kidney: 600μg.kg-1

Muscle-100, Fat-300, Liver-300, Kidney:600μg.kg-1

Muscle/Fat-100, Liver: 200, Kidney:300μg.kg-1

vÁeÁ PÉÆÃ½ ªÀiÁA¸À ªÀÄvÀÄÛ ªÀiÁA¸ÀzÀ G¥À GvÀà£ÀßUÀ¼À°è CAUÁ±À ²®ÄÌ vÀqÉUÀlÄÖªÀ°è ÷¨sÁgÀvÀ ¸ÀPÁðgÀzÀ ¤§AzsÀ£ÉUÀ¼ÀÄ

EIC: Regulatory Programme for Control of Residues In Fresh Poultry Meat & Poultry meat Products (For export to Non-EU countries (in units approved for export to all countries except EU)

dt. 14.3.2012

Set/Group

Substances to be monitored Compound /marker residue Level of action above which deemed non- compliance MRPL/ MRL [μg.kg-1]

-contd.Set-6/B1

DåAn ¨ÁåQÖÃjAiÀiÁUÀ¼ÀÄ

Flumiquine Muscle:400, Fat:250, Liver:800, Kidney:1000 μg.kg-1

Oxolinic Acid Muscle:100, Fat:50, Liver / Kidney:150 μg.kg-1

Sulphonamides[Sulfadimidine, Sulfadiazine, Sulfadimethoxine, Sulfadoxine, Sulfamethazine, Sulfanilamide, Sulfamirazine, Sulfamethoxypyridazine, Sulfamethiazole, Sulfathiazol]

Muscle/Fat/Liver/Kidney:100 μg.kg-1 (Combined limit)

Sum of Chlorotetracycline and 4-epi- Chlorotetracycline Sum of Oxytetracycline and 4-epi- Oxytetracycline Sum of Tetracycline and 4-epi-Tetracycline

Muscle:100, Liver:300Kidney: 600 μg.kg-1

-do--do-

Trimethoprim Muscle/Fat/Liver/Kidney:50 μg.kg-1

ªÉÆmÉÖ PÉÆÃ½UÀ¼À°è ¸ÀÆPÁë÷ätÄ ¤gÉÆÃzsÀPÀUÀ¼À »A¥ÀqÉAiÀÄÄªÀ CªÀ¢ü

Antimicrobials in Layers (risk) and suggested withdrawal periodOµÀ¢ü F.AiÀÄÄ

JA.Dgï.J¯ïAiÀÄÄ J¸ï J JA.Dgï.J¯ï

OµÀ¢üAiÀÄ ¥ÀæªÀiÁt ü / PÁ¯ÁªÀ¢ü

¸ÀÆa¹gÀÄªÀ ».C.

mÉÊ¯ÉÆÃ¹£ï CAVÃPÀÈvÀ200ug.kg-1

CAVÃPÀÈvÀ

200ug.kg-1

¤ÃgÀÄ :500mg.Lx 5¢£ÀUÀ¼ÀÄDºÁgÀ: 200mg.kgx7¢£ÀUÀ¼ÀÄ

E.ªÉÆ: 8 ¢£ÀUÀ¼ÀÄªÉÆmÉÖ: 0

DQìmÉÃmÁæ¸ÉÊQèÃ£ï

CAVÃPÀÈvÀ200ug.kg-1

C£Àé¬Ä¸ÀÄªÀÅ¢®è

¤ÃgÀÄ 100mg.Lx5¢£ÀUÀ¼ÀÄªÉÄÃªÀÅ/DºÁgÀ:25mg.kgx28¢£ÀUÀ¼ÀÄ

AiÉÆÃPï =0; D®Äâ«Ä£ï=0E.ªÉÆ. =0

PÉÆèÃgïmÉÃmÁæ¸ÉÊQèÃ£ï

CAVÃPÀÈvÀ

200ug.kg-1

CAVÃPÀÈvÀ

400ug.kg-1

¤ÃgÀÄ : 500mg.Lx7¢£ÀUÀ¼ÀÄªÉÄÃªÀÅ/DºÁg: 600mg.Lx9d¢£ÀUÀ¼ÀÄ

ªÉÆmÉÖ=6¢£ÀUÀ¼ÀÄªÉÆmÉÖ=>9¢£ÀUÀ¼ÀÄ

mÉÃmÁæ¸ÉÊQèÃ£ï D¦ü¹°Ã£ï dAmÁªÉÄÊ¹£ï



¤ÃgÀÄ : 250mg.Lx5d¢£ÀUÀ¼ÀÄ

ªÉÆmÉÖ=6¢£ÀUÀ¼ÀÄ

KjxÉÆæÃªÉÄÊ¹£ï



¤ÃgÀÄ : 500mg.Lx5¢£ÀUÀ¼ÀÄ

AiÉÆÃPï=7; D®Äâ«Ä£ï=3

DåA¦ü¹°Ã£ï C£Àé¬Ä¸ÀÄªÀÅ¢®è


¤ÃgÀÄ : 100mg.Lx5¢£ÀUÀ¼ÀÄ

E.ªÉÆ.=0

dAmÁªÉÄÊ¹£ï



Inj: 10mg.kg-1xs.c or i.m AiÉÆÃPï=7; D®Äâ«Ä£ï=3

PÉÆèÃgÁA¦üí¤PÁ¯ï

¤µÉÃzsÀªÀiÁrzÉ

¤µÉÃzsÀªÀiÁrzÉ

¤ÃgÀÄ :40mg.Lx7d¢£ÀUÀ¼ÀÄ

AiÉÆÃPï=7; D®Äâ«Ä£ï=4

¤AiÉÆÃªÉÄÊ¹£ï

C£Àé¬Ä¸ÀÄªÀÅ¢®è500ug.kg-1


¤ÃgÀÄ : 0.25g.Lx5¢£ÀUÀ¼ÀÄ

E.ªÉÆ=0 ¢£ÀUÀ¼ÀÄ

OµÀ¢üUÀ¼À ±ÉÃµÁA±À vÀqÉUÀmÉÖUÀ®Ä ÷ºÉZÀÄÑªÀj vÀ¯ÉaÃn OµÀ¢üUÀ¼À PÀrªÉÄ

§¼ÀPÉReduced extra-Label use to meet MRL standards

ºÉZÀÄÑªÀj vÀ¯ÉaÃn (Extra-Label) OµÀ¢üUÀ¼ÀÄ:-AiÀiÁªÀÅzÉÃ OµÀ¢üAiÀÄ£ÀÄß CzÀgÀ ¤UÀ¢üvÀ ¥ÀæªÀiÁtQÌAvÀ ºÉZÁÑV, ¤UÀ¢üvÀ ªÀiÁUÀðzÀ §zÀ¯ÁV ¨ÉÃgÉ «zsÁ£À §¼À¹, MAzÀÄ CAUÁUÀ ¸ÉÆÃAQUÉ ¤UÀ¢ü ¥Àr¹gÀÄªÀ OµÀ¢üAiÀÄ£ÀÄß ¨ÉÃgÉÆAzÀÄ CAUÁUÀ ¸ÉÆÃAQvÀPÉÌ §¼À¹, ¨ÉÃgÉ ¥ÁætÂUÀ¼ÀUÉ PÁ¬ÄÝj¹gÀÄªÀ OµÀ¢üAiÀÄ£ÀÄß PÉÆÃ½UÀ½UÉ ¤ÃqÀÄªÀ, ªÀÄÄAvÁzÀ PÀæªÀÄUÀ¼ÀÄ ºÉZÀÄÑªÀj vÀ¯ÉaÃn OµÀ¢üUÀ¼ÁUÀÄvÀÛªÉ.

F vÉgÀ£ÁV §¼À¸ÀÄªÀ OµÀ¢üUÀ½AzÀ PÉÆÃ½

ªÀiÁA¸À ªÀÄvÀÄÛ ªÉÆmÉÖUÀ¼À°è OµÀ¢üÃAiÀÄ ±ÉÃµÀ/ ²®ÄÌ ºÉZÁÑUÀÄªÀ ¸ÁzsÀåvÉ EgÀÄvÀÛzÉ. ºÁUÁV CvÀåAvÀ CªÀ±ÀåPÀvÉ EzÀÝ°è ªÀiÁvÀæ §¼À¸ÀvÀPÀÌzÀÄÝÄ.

OµÀ¢ü ZÀ®£É ªÉÄÃ¯É PÁQìÃrAiÉÆÃ¸ÁÖmï UÀ¼À ªÀÄvÀÄÛ

mÁQì£ï ¨ÉÊAqÀgï UÀ¼À ¥ÀjuÁªÀÄ

Impact of coccidiostats/toxin binders on drug kinetics & consequencemÁAiÀÄªÀÄÄ°£ï

ªÉÆÃ£É¤ì£ï£ÁgÀ¹£ï

vÀÆPÀ PÀrªÉÄªÀiÁqÀÄªÀÅzÀÄ,«µÀPÁgÀvÉ, vÀÆPÀ PÀrªÉÄªÀiÁqÀÄªÀÅzÀÄ, «µÀPÁgÀvÉ,¹®ÄÌ G½PÉUÉ ÇÀàzÀ

mÁAiÀÄªÀÄÄ°£ï

ªÀÄzÀÄgÀªÉÄÊ¹£ï¸ÉÃªÀÄÆØgÀªÉÄÊ¹£ï

ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼À°è AiÀiÁªÀÅzÉÃ vÉÆAzÀgÉ¬Ä®èªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼À°è AiÀiÁªÀÅzÉÃ vÉÆAzÀgÉ¬Ä®è


¯Áå¸Á¯ÉÆ¹qï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼À°è AiÀiÁªÀÅzÉÃ vÉÆAzÀgÉ¬Ä®è


¸Áå°£ÉÆÃªÉÄÊ¹£ï [Salinomycin]

fÃªÀ¥ÀZÀAiÀÄ QæAiÉÄUÉ vÀqÉ GAlÄªÀiÁqÀÄªÀÅzÀÄ, ¹®ÄÌ G½PÉUÉ ÇÀàzÀInhibit drug metabolism

mÉÊ¯ÉÆÃ¹£ï JjÃxÉÆæÃªÉÄÊ¹£ï nÃ¯ïªÉÄÊPÉÆÃ¹£ï

¸ÁªÀiÁ£Àå §gÀºÀ ¸ÀÆaUÀ¼ÀÄ[many prescriptions]

fÃªÀ¥ÀZÀAiÀÄ QæAiÉÄAiÀÄ QtéUÀ¼À£ÀÄß vÀqÉAiÀÄÄªÀÅzÀÄ ªÀÄvÀÄÛ ¹®ÄÌ G½PÉUÉ ÇÀàzÀInhibit drug metabolism

¤ÃPÁ¨Áðfì£ïgÉÆÃ¨É¤r£ï

¨ÉAmÉÆÃ£ÉÊmï[Bentonite]/ «µÀ §AzsÀPÀUÀ¼ÀÄ[toxin binders]

eÉÊ«PÀ ®¨sÀåvÉAiÀÄ£ÀÄß PÀrªÉÄªÀiÁqÀÄªÀÅzÀÄ

J£ÉÆæÃ¥sÉèPÁìQì£ï

GvÉÛÃf¹zÀ ªÀÄ¹/ ºÉZï.J¸ï.¹.J.J¸ï [HSCAS] / Chlorine rich water

OµÀ¢üAiÀÄ UÀÄt ªÀÄvÀÄÛ eÉÊ«PÀ ®¨sÀåvÉAiÀÄ£ÀÄß PÀrªÉÄªÀiÁqÀÄªÀÅzÀÄ

mÉÊ¯ÉÆÃ¹£ï°APÉÆÃªÉÄÊ¹£ï

¨ÉAmÉÆÃ£ÉÊmï[Bentonite] OµÀ¢üAiÀÄ UÀÄt ªÀÄvÀÄÛ eÉÊ«PÀ ®¨sÀåvÉAiÀÄ£ÀÄß PÀrªÉÄªÀiÁqÀÄªÀÅzÀÄ

PÁQìrÃAiÉÆÃ¸ÁÖmï UÀ¼À »AvÉUÉAiÀÄÄªÀ CªÀ¢üAiÀÄ §gÀºÀ ¸ÀÆa

Prescribed Withdrawal period for Cocciodiostates PÁQìrÃAiÉÆÃ¸ÁÖmï

UÀ¼ÀÄ CocciodiostatesªÀiÁA¸À/ªÉÆmÉÖ PÉÆÃ½UÀ¼ÀÄ

Broiler/Layer

»AvÉUÉAiÀÄÄªÀ CªÀ¢(¢£ÀUÀ¼À°è)Withdrawal period(days)

DªÉÆáçÃ°AiÀiÁªÀiï ªÉÆmÉÖ PÉÆÃ½UÀ¼ÀÄ{¤ÃgÀÄ

CxÀªÁ DºÁgÀzÀ°è}

‘0’

qÉÊ¤ÃmÉÆÃ¯ÁªÉÄÊqï ªÉÆmÉÖ PÉÆÃ½UÀ¼ÀÄ[at ‘risk period’]

ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ

1-3‘0’

¤ÃPÁ¨Áðfì£ï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ 4

ºÁå¯ÉÆÃ¥ÀÇf£ÉÆÃ£ï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ 4

¯Áå¸À¯ÉÆÃ¹qï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ ‘0’

ªÀÄzÀÄgÁªÉÄÊ¹£ï /¸ÉÃªÀÄÆØgÁªÉÄÊ¹£ï

ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ 5 / 5

ªÉÆÃ£É¤ì£ï/£ÁgÀ¹£ï/¸Áå°£ÉÆÃ¹£ï

ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ ‘0’

PÉÆèÃ¦üqÁ¯ï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ 5

qÉÊPÁèdÄj¯ï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ ‘0’

¸À¯ÁáªÉÄÃxÁf£ï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ 10

¸À¯ÁáQé£ÁPÁì¯ÉÆÃ£ï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ [0.17g.L-1]

10

DQìmÉÃmÁæ¸ÉÊQèÃ£ï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ [200g.ton-1]

3

qÉPÉÆÃQé£ÉÃmï ªÀiÁA¸ÀzÀ PÉÆÃ½UÀ¼ÀÄ ‘0’

ºÉZÀÄÑªÀj vÀ¯ÉaÃn OµÀ¢üUÀ¼À£ÀÄß §¼À¹zÀ°è CAUÁUÀ ²®ÄÌ vÀqÉUÀlÄÖªÀ §UÉ

Residue Avoidance used Extra –labelEU Directive 2001/82EC Amended 2004 /28/EC

¤²ÑvÀªÁzÀ PÉÆÃ½ vÀ½UÀ£ÀÄUÀÄtªÁV ªÀiÁ£Àå ªÀiÁrgÀÄªÀ DºÁgÀ ¸ÀAPÀ°vÀUÀ¼À£Éß [feed additives] G¥ÀAiÉÆÃV¸ÀÄªÀÅzÀÄ

²¥sÁgÀ¸ÀÄì ªÀiÁrgÀÄªÀ OµÀ¢ü »AqÉAiÀÄÄªÀ PÁ¯ÁªÀ¢üAiÀÄ£ÀÄß ZÁZÀÄ vÀ¥ÀàzÉÃ ¥Á°¸ÀÄªÀÅzÀÄ

vÀÄA¨Á CªÀ±ÀåPÀ«zÁÝUÀ ªÀiÁvÀæªÉÃ ºÉZÀÄÑªÀj vÀ¯ÉaÃn OµÀ¢üUÀ¼À£ÀÄß G¥ÀAiÉÆÃV¸ÀÄªÀÅzÀÄ

¤²ÑvÀªÁzÀ/ ¸ÀjAiÀiÁzÀ zÁR®wAiÀÄ£ÀÄß ¤ªÀðºÀuÉ ªÀiÁqÀÄªÀÅzÀÄ

CAUÁUÀ ²°Ì£À §UÉÎ £ÀdgÀÄ PÁAiÀÄðPÀæªÀÄUÀ¼À£ÀÄß [surveillance programmes] C¼ÀªÀr¹PÉÆ¼ÀÄîªÀÅzÀÄ

Commodity Withdrawal days if used extra-label

Poultry- Eggs 7 days

Milk 7days

Meat: Poultry, Mammals

28days

Fish 500°C days

CAUÁUÀ ²®ÄÌ PÀAqÀÄ »rAiÀÄªÀ ¥ÀjÃPÉëUÀ¼ÀÄ Screening tests for residue detection

{{{Internal Quality Control Tests}

ªÀiÁA¸À RAqÀUÀ¼ÀÄ (Poultry muscle)• 3-plate test (K. rhizophila, B. cereus, and E. coli) for detection and

presumptive identification of tetracyclines, β-lactam and quinolones• Plate assays based on B. subtilis, B. cereus, and E. coli (specific

detection of quinolones) ªÀÄÆvÀæ ¦AqÀzÀ zÀæªÀ (Renal pelvis fluid )(Nouws method)

• Renal pelvis fluid: 5-plate test NAT (B. subtilis, B. cereus, B. pumilus, K. rhizophila, and Y. ruckeri) ªÀiÁA¸À RAqÀUÀ¼ÀÄ ªÀÄvÀÄÛ

ªÉÆmÉÖUÀ¼ÀÄ(Poultry muscle & egg)• Plate assay based on Y. ruckeri and Premi®Test (specific detection of

quinolones) ªÀiÁA¸À RAqÀzÀ zÀæªÀ (Poultry muscle fluid)

• EU 4-plate test, B. stearothermophilus disk assay and Premi®Test comparison CAUÁUÀ zÀæªÀ (Poultry tissue fluid)

• Premi®Test (B. stearothermophilus) ªÉÆmÉÖ/CAUÁUÀ¼ÀÄ Egg/Poultry tissue

• Klebsiella pneumoniae plate test (Specific detection of quinolones)

• Bacillus stearothemophilus• 147⁰F (64 ⁰C) for 3 hrs

¸ÀÆPÁë÷ätÄ fÃ«¤gÉÆÃzsÀPÀUÀ¼À £ÁåAiÀÄ§zÀÝ G¥ÀAiÉÆÃUÀ : ¸ÁgÁA±À

Judicious Antibiotic Use: Summary

1. ¥À±ÀÄ ªÉÊzÀågÀÄ ªÀÄvÀÄÛ PÉÆÃ½ ¸ÁPÁuÉzÁgÀgÀ°è £ÁåAiÀÄ¸ÀªÀÄävÀ ¨ÁAzsÀªÀå

1. A valid poultry veterinarian-client-relationship 1.Closely monitor antibiotic usage in poultry flocks 2. Production mangers, veterinarians in close contact with service persons and individual users

2. ºÉZÀÄÑªÀj vÀ¯ÉaÃn OµÀ¢üUÀ¼À G¥ÀAiÉÆÃUÀªÀ£ÀÄß PÀrªÉÄ ªÀiÁqÀÄªÀÅzÀÄ/zÀÆgÀ«j¸ÀÄªÀÅzÀÄ

2. Extra-label use must be avoided or limited 1. Govt of India - ECI 2. Food Safety Act, 2006


Judicious Antibiotic Use: Summary

3. ¸ÀªÀÄAd¸ÀªÁVzÀÝ°è £ÁågÉÆÃ ¸ÉàÃPïÖçA DAn §AiÉÆÃnPï UÀ¼À£ÉßÃ

G¥ÀAiÉÆÃV¸ÀÄªÀÅzÀÄ 3. Use narrow spectrum antibiotics when relevant 1. Use culture & sensitivity test result for therapeutic success 2. Determine changes in antimicrobial susceptibility patterns

4. gÉÆÃUÀ ¤gÉÆÃzsÀPÀ ±ÀQÛ PÀrªÉÄ EgÀÄªÀ PÉÆÃ½UÀ¼À°è ¨ÁåQÖÃjAiÀiÁ¸ÁÖnPï UÀ¼À£ÀÄß

G¥ÀAiÉÆÃV¸ÀzÉ EgÀÄªÀÅzÀÄ M½vÀÄ. 4. Avoid bacteriostatics in flocks with poor immunity 1. Chronic or frequent infections 2. Infection consequent to Infectious bursal disease [IBD]


5. PÉÆÃ½UÀ¼ÀÄ PÁ¬Ä¯É¬ÄAzÀ §¼À®ÄwÛzÀÝ°è aQvÀìPÀ ¸ÀÆPÁë÷ätÄ fÃ«¤gÉÆÃzsÀPÀUÀ¼À

§¼ÀPÉAiÀÄ£ÀÄß «ÄwAiÀÄ°èqÀÄªÀÅqÀÄ5. Limit therapeutic antibiotics to ill or birds at risk

Birds housed adjacently and not clinically ailing should not be medicated Do not medicate during non-bacterial uncomplicated viral infections.

6. EvÀgÉ aQvÀìPÁ DAiÉÄÌUÀ¼À£ÀÄß RqÁØAiÀÄªÁV ¥ÀjUÀtÂ¸ÀÄªÀÅzÀÄ

6. Other therapeutic options must be considered Use antibiotics only as a tool to contain active disease Explore management adjustments:- Temperature-Ventilation-Litter moisture Supportive therapy with vitamins and electrolytes

¸ÀÆPÁë÷ätÄ fÃ«¤gÉÆÃzsÀPÀUÀ¼À

£ÁåAiÀÄ§zÀÝ G¥ÀAiÉÆÃUÀ : ¸ÁgÁA±À

7. aQvÀì PÀæªÀÄUÀ¼À£ÀÄß PÀqÁØAiÀÄªÁV PÀæªÀÄ§zÀÝUÉÆ½¸ÀÄªÀÅzÀÄ

7. Therapeutic regimens must be optimized Use current pharmacological information Therapeutic dosage-duration- MIC values Drug-drug interactions, herbs-drug interactions

8. aQvÉì ¤ÃrgÀÄªÀ zÁR¯ÁwUÀ¼À£ÀÄß ¤ªÀðºÀuÉªÀiÁqÀÄªÀÅzÀÄ ªÀÄvÀÄÛ

aQvÀì PÀæªÀÄUÀ¼À£ÀÄß «ªÀÄ²ð¸ÀÄªÀÅzÀÄ8. Accurate records of treatment, evaluate therapeutic regimens

9. ¸ÀÆPÁë÷ätÄ fÃ«¤gÉÆÃzsÀPÀUÀ¼ÀÄ ªÁvÁªÀgÀtzÉÆA¢UÉ

PÀ®Ä¶vÀªÁUÀÄªÀÅzÀ£ÀÄß PÀrªÉÄªÀiÁqÀÄªÀÅzÀÄ9. Minimise environmental contamination with antimicrobials

zsÀ£ÀåªÁzÀUÀ¼ÀÄ ….

Vision is the ability to see what is possible before it becomes obvious….